The contract manufacturing market for Pharmaceuticals in China is projected to grow at an annualized rate of ~8.9%, till 2030

Roots Analysis has done a detailed study on China Pharmaceutical Contract Manufacturing Services Market, 2020-2030, covering key aspects of the industry and identifying key future growth opportunities.

To order this 200+ page report, which features 85+ figures and 100+ tables, please visit  China Pharmaceutical Contract Manufacturing Services Market, 2020-2030

Key Market Insights

§  Presently, over 100 CMOs across the globe claim to have manufacturing facilities in China, offering services for pharmaceutical API, intermediates and FDF manufacturing

§  CMOs have established manufacturing facilities across different regions of China; Eastern China has emerged as a popular hub, serving as a base of operations for many contract service providers

§  The current, installed manufacturing capacity of pharmaceutical CMOs in China is estimated to be over 46 million liters; interestingly, capacity utilization has been observed to be ~75% over the last few years

§  Big pharma players have also invested significantly in this region for initiatives related to the establishment or expansion of R&D centers and manufacturing facilities focused on pharmaceutical products

§  Innovator companies are expected to continue outsourcing clinical and commercial manufacturing operations to China-based CMOs; the contract services industry in the region is likely to grow at a CAGR of ~8.9%

§  In the long-term, the projected future opportunity is anticipated to be well distributed across various market segments, such as different types of products (APIs and FDFs), region (eastern china, southern china, western china) and others

For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

Table of Contents

1.                     PREFACE
1.1.                  Scope of the Report
1.2.                  Research Methodology
1.3.                  Chapter Outlines

2.                     EXECUTIVE SUMMARY

3.                     INTRODUCTION
3.1.                  Chapter Overview
3.2.                  Need for Outsourcing in the Pharmaceutical Industry
3.3.                  Overview of the Pharmaceutical Contract Manufacturing
3.4.                  Evolution of the Pharmaceutical Contract Manufacturing Industry
3.4.1.                Traditional Contract Manufacturing Organizations (CMOs)

3.4.2.                Modern CMOs
3.5.                  Services Offered by CMOs
3.6.                  Pharmaceutical Contract Manufacturing Scenario in China

3.7.                  Advantages and Challenges associated with Outsourcing Pharmaceutical Manufacturing to China-based CMOs

4.                     CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1.                  Chapter Overview
4.2.                  Small Molecule and Large Molecule Drugs / Therapies

4.2.1.                Comparison of General Characteristics
4.2.2.                Comparison of Manufacturing Processes
4.2.3.                Comparison of Key Manufacturing-related Challenges

5.                     MARKET OVERVIEW
5.1.                   Chapter Overview
5.2.                   Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies

5.2.1.                Analysis by Year of Establishment
5.2.2.                Analysis by Company Size
5.2.3.                Analysis by Location of Headquarters

5.2.4.                Analysis by Type of Product (API and FDF)
5.2.5.                Analysis by Type of FDF
5.2.6.                Analysis by Type of Packaging

5.2.7.                Analysis by Manufacturing Facilities

5.3.                   Non-Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies

5.3.1.                Analysis by Year of Establishment

5.3.2.                Analysis by Company Size

5.3.3.                Analysis by Location of Headquarters

5.3.4.                Analysis by Type of Product (API and FDF)

5.3.5.                Analysis by Type of FDF

5.3.6.                Analysis by Type of Packaging

5.3.7                 Analysis by Manufacturing Facilities

6.                     MANUFACTURING FACILITIES OF PHARMACEUTICAL CMOs IN CHINA
6.1.                   Chapter Overview
6.2.                   Chinese Pharmaceutical CMOs: List of Manufacturing Facilities

6.2.1.                Analysis by CMO Manufacturing Facilities in Eastern China
6.2.2.                Analysis by CMO Manufacturing Facilities in Southern China
6.2.3.                Analysis by CMO Manufacturing Facilities in Northern China

7.                     PHARMACEUTICAL MANUFACTURING REGULATIONS IN CHINA

7.1.                   Chapter Overview

7.1.1.                Health Authorities in China

7.1.2.                Overview of Regulatory Guidelines in China

8.                     COMPANY PROFILES

8.1.                   Chapter Overview

8.2.                   2Y-Chem

8.2.1.                Company Overview

8.2.2.                Service Portfolio

8.2.3.                China-based Manufacturing Facilities and Capabilities

8.2.4.                Recent Developments and Future Outlook

8.3.                   Aurisco Pharmaceutical

8.3.1.                Company Overview

8.3.2.                Service Portfolio

8.3.3.                China-based Manufacturing Facilities and Capabilities

8.3.4.                Recent Developments and Future Outlook

8.4.                   ChemPartner

8.4.1.                Company Overview

8.4.2.                Service Portfolio

8.4.3.                China-based Manufacturing Facilities and Capabilities

8.4.4.                Recent Developments and Future Outlook

8.5.                   Dorrapharma

8.5.1.                Company Overview

8.5.2.                Service Portfolio

8.5.3.                China-based Manufacturing Facilities and Capabilities

8.5.4.                Recent Developments and Future Outlook

8.6.                   Hubei Biocause Pharmaceutical

8.6.1.                Company Overview

8.6.2.                Service Portfolio

8.6.3.                China-based Manufacturing Facilities and Capabilities

8.6.4.                Recent Developments and Future Outlook

8.7.                   Infoark

8.7.1.                Company Overview

8.7.2.                Service Portfolio

8.7.3.                China-based Manufacturing Facilities and Capabilities

8.7.4.                Recent Developments and Future Outlook

8.8.                   Ningbo Menovo Pharmaceutical

8.8.1.                Company Overview

8.8.2.                Service Portfolio

8.8.3.                China-based Manufacturing Facilities and Capabilities

8.8.4.                Recent Developments and Future Outlook

8.9.                   Shandong Xinhua Pharmaceutical

8.9.1.                Company Overview

8.9.2.                Service Portfolio

8.9.3.                China-based Manufacturing Facilities and Capabilities

8.9.4.                Recent Developments and Future Outlook

8.10.                 Shanghai Acebright Pharmaceuticals 

8.10.1.             Company Overview

8.10.2.             Service Portfolio

8.10.3.             China-based Manufacturing Facilities and Capabilities

8.10.4.             Recent Developments and Future Outlook

8.11.                 STA Pharmaceutical

8.11.1.             Company Overview

8.11.2.             Service Portfolio

8.11.3.             China-based Manufacturing Facilities and Capabilities

8.11.4.             Recent Developments and Future Outlook

8.12.                 Zhejiang Huahai Pharmaceutical

8.12.1.             Company Overview

8.12.2.             Service Portfolio

8.12.3.             China-based Manufacturing Facilities and Capabilities

8.12.4.             Recent Developments and Future Outlook

9.                     BIG PHARMA INITIATIVES IN CHINA

9.1.                   Chapter Overview

9.2.                   Big Pharma Players: List of Initiatives

9.2.1.                Analysis by Number of Initiatives

9.2.2.                Analysis by Year of Initiative

9.2.3.                Analysis by Company and Year of Initiative

9.2.4.                Analysis by Type of Initiative

9.3.                   Benchmark Analysis of Big Pharma Players

9.3.1.                Harvey Ball Analysis: Summary of Investments Made

9.3.2.                Geographical Analysis by Investments Made (Facility Specific)

10.                    RECENT TRENDS

10.1.                 Chapter Overview

10.2.                 CMOs with Manufacturing Facilities in China: List of Partnerships

10.3.                 Analysis by Year and Type of Partnership

10.4.                 Logo Landscape of Key Partners

10.5.                 Geographical Analysis

11.                    CAPACITY ANALYSIS

11.1.                 Chapter Overview

11.2.                 Key Assumptions and Methodology

11.3.                 CMOs with Manufacturing Facilities in China: Installed Capacity

11.3.1.              Analysis by Company Size

11.3.2.             Analysis by Location of Chinese Manufacturing Facilities

11.3.2.1.           Capacity Analysis: Eastern China

11.3.2.2.           Capacity Analysis: Southcentral China

11.3.2.3.           Capacity Analysis: Northern China

12.                    SWOT ANALYSIS

12.1.                 Chapter Overview

12.2.                 Comparison of SWOT Factors

12.3.                 Concluding Remarks

13.                    MARKET FORECAST

13.1.                 Chapter Overview

13.2.                 Forecast Methodology and Key Assumptions

13.3.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030

13.4.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

13.4.1.              Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030

13.4.2.              Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030

13.4.3.              Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030

13.5.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Product

13.5.1.              API Contract Manufacturing Services Market in China, 2020-2030

13.5.1.1.           API Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

13.5.1.1.1.         API Contract Manufacturing Services Market in Eastern China, 2020-2030

13.5.1.1.2.         API Contract Manufacturing Services Market in Southern China, 2020-2030

13.5.1.1.3.         API Contract Manufacturing Services Market in Northern China, 2020-2030

13.5.2.              Drug Product Contract Manufacturing Services Market in China, 2020-2030

13.5.2.1.           Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

13.5.2.1.1.         Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030

13.5.2.1.2.         Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030

13.5.2.1.3.         Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030

13.5.2.2.           Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Drug Product

13.5.2.2.1.         Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Solid Drug Product

13.5.2.2.2.         Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Liquid and Semi Solid Drug Product

13.5.2.2.3.         Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Injectable Drug Product

13.5.2.2.4.         Drug product Contract Manufacturing Services Market in China, 2020-2030: Share of Other Drug Products

13.6.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Scale of Operation

13.6.1.              Clinical Scale Contract Manufacturing Services Market in China, 2020-2030

13.6.2.              Commercial Scale Contract Manufacturing Services Market in China, 2020-2030  

13.7.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Size of Manufacturers

13.7.1.              Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies

13.7.2.              Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-sized Companies

13.7.3.              Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies

14.                    CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK

14.1.                 Chapter Overview

14.2.                 Current Opinions and Recuperative Initiatives of Key Players

14.2.1.              Wuxi AppTec

14.2.2.              Porton Pharma Solutions

14.2.3.              Lonza

14.3.                 Impact on Future Market Opportunity for Pharmaceutical CMOs in China

15.                    CONCLUSION

16.                    APPENDIX 1: TABULATED DATA

17.                    APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com